This week’s DeviceTalks Weekly podcast episode talks with industry leaders about improving worker diversity and developing new ways to treat COVID-19 patients. Kevin Lobo, chairman and CEO of Stryker, explains how his company — and the industry group AdvaMed that he currently leads — has been working to increase diversity of its workforce, particularly in […]
Dexcom CEO sees a new market for continuous glucose monitors after COVID-19
Could in-hospital use of continuous glucose monitors become a new normal after the COVID-19 pandemic? Dexcom CEO Kevin Sayer thinks so. As the pandemic ramped up in March, FDA issued temporary guidance allowing increased remote monitoring of hospital patients in order to limit contact with hospital staff. The guidance included CGMs made by companies such […]
Abbott FreeStyle Libre 2 iCGM FDA cleared for use in adults and children
Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 system for adults and children ages four and older with diabetes. The Abbott Park, Ill.-based company touts its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system as the only such system with optional real-time alarms that measure glucose levels every minute […]
Dexcom lands CE Mark for G6 glucose monitor
Dexcom (NSDQ:DXCM) announced today that it received CE Mark approval in Europe for its G6 continuous glucose monitoring system. The Dexcom G6 uses a small, wearable sensor and transmitter, now indicated to be placed on the back of the upper arm, to continuously measure and send glucose levels wirelessly to a dedicated receiver or compatible smart […]
Dexcom completes sale of $1.05B in notes
Dexcom (NSDQ:DXCM) announced that it completed the sale of $1.05 billion aggregate principal amount of its convertible senior notes. The San Diego-based continuous glucose monitoring system developer announced earlier this week that it was offering $850 million in notes with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate […]
DexCom prices $1.05B ‘upsized’ offering
Continuous glucose monitoring system developer Dexcom (NSDQ:DXCM) announced today that it priced an upsized offering worth $1.05 billion in convertible senior notes. Yesterday, the San Diego-based company announced an offering worth $850 million with plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Today, […]
Dexcom to raise $850m from senior notes offering
Dexcom (NSDQ:DXCM) said today that it plans to offer an $850 million aggregate principal amount of convertible senior notes due 2025. The San Diego-based continuous glucose monitoring systems company also plans to offer note purchasers a 13-day option to buy up to an additional $150 million aggregate principal amount of notes. Dexcom plans to use $600 […]
Dexcom shares up on Street-beating Q1 results
Dexcom (NSDQ:DXCM) posted first-quarter results today that beat the consensus forecast on Wall Street but dropped its financial guidance for the year. The San Diego-based continuous glucose monitoring systems company reported profits of $19.9 million, or 21¢ per share, on sales of $405.1 million for the three months ended March 31 on sales growth of 44.4% […]
Dexcom appoints senior VP of finance and chief accounting officer
Dexcom (NSDQ:DXCM) this week said it appointed Jereme Sylvain as senior VP of finance and chief accounting officer, which took effect on March 9. Sylvain will be the accounting officer for purposes of the rules and regulations of the Securities and Exchange Commission. Prior to his appointment, Sylvain was Dexcom’s VP and corporate controller and […]
Dexcom lands CE Mark for continuous glucose monitor use by pregnant women
Dexcom (NSDQ:DXCM) said Friday that its G6 continuous glucose monitor system has received the CE Mark for use during pregnancy, and will be available soon, starting with the United Kingdom in Spring 2020. Glucose levels are hard to manage in pregnancy due to the increasing need for and resistance to insulin. Poorly controlled glucose levels in […]
Insulet partners with Abbott and Dexcom on automated insulin delivery
Abbott (NYSE:ABT) and Dexcom (NSDQ:DXCM) each announced today that they are partnering with Insulet (NSDQ:PODD) to feed blood glucose monitor data into an automated insulin delivery system. For Acton, Mass.–based Insulet, the agreements are a boost for its next-generation Omnipod Horizon automated insulin delivery system, which is presently an investigational device in the United States. The idea of […]
- 1
- 2
- 3
- …
- 15
- Next Page »
